DMK Pharmaceuticals Corporation announced that it is reacquiring the rights to its SYMJEPI® (epinephrine) Injection 0.3mg and SYMJEPI® (epinephrine) Injection 0.15mg products from USWM, LLC (“USWM” or “US WorldMeds”). US WorldMeds previously held exclusive distribution and commercialization rights for SYMJEPI® and ZIMHI® (naloxone) products in the United States, and was responsible for marketing, promotion and distribution efforts.
The Company is now actively seeking out-license opportunities for SYMJEPI® in the US and globally, in addition to exploring other options with a focus on maximizing value for shareholders.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!